Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone Treatment in Men With Multiple Sclerosis
NCT02317263Phase 2Withdrawn
- Sponsor
- University of California, Los Angeles
- Primary completion
- Jan 2099
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of Testosterone TEPI patch in multiple sclerosis (MS) (2 arms), sponsored by University of California, Los Angeles. Primary endpoint: Whole Brain Atrophy at 96 weeks. Status: withdrawn.
02
Drugs
Testosterone TEPI patch
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02317263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02317263.